SSC

Spruce Street Capital Portfolio holdings

AUM $416M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$416M
AUM Growth
+$113M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
34
New
Increased
Reduced
Closed

Top Buys

1
+$20.4M
2
+$14.4M
3
+$11.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$10.5M
5
RLMD icon
Relmada Therapeutics
RLMD
+$10.3M

Top Sells

1
+$51.3M
2
+$41M
3
+$17.9M
4
OCUL icon
Ocular Therapeutix
OCUL
+$9.52M
5
PCVX icon
Vaxcyte
PCVX
+$8.4M

Sector Composition

1 Healthcare 98.78%
2 Financials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
1
Relmada Therapeutics
RLMD
$735M
$43M 10.34%
6,262,114
+2,175,933
KNSA icon
2
Kiniksa Pharmaceuticals
KNSA
$4.07B
$36.6M 8.81%
761,063
+326,081
LBRX
3
LB Pharmaceuticals
LBRX
$814M
$33.6M 8.09%
1,376,159
+370,566
DNTH icon
4
Dianthus Therapeutics
DNTH
$4.75B
$31.3M 7.53%
373,274
+75,837
RLAY icon
5
Relay Therapeutics
RLAY
$2.96B
$29.7M 7.14%
2,984,125
ANRO icon
6
Alto Neuroscience
ANRO
$729M
$29.1M 7%
1,325,210
+1,102,366
CNTA
7
Centessa Pharmaceuticals
CNTA
$6.15B
$19.5M 4.68%
489,849
+411,852
SVRA icon
8
Savara
SVRA
$1.03B
$18.5M 4.44%
3,383,175
+972,082
KALV icon
9
KalVista Pharmaceuticals
KALV
$1.43B
$18.1M 4.34%
897,681
+509,713
PCVX icon
10
Vaxcyte
PCVX
$7.19B
$14.3M 3.43%
245,709
-154,651
ELVN icon
11
Enliven Therapeutics
ELVN
$2.54B
$12.9M 3.1%
329,006
-117,078
SRZN icon
12
Surrozen
SRZN
$303M
$12.6M 3.03%
432,040
ENTA icon
13
Enanta Pharmaceuticals
ENTA
$408M
$11.8M 2.83%
932,598
+542,911
ALKS icon
14
Alkermes
ALKS
$6.2B
$11.2M 2.7%
+317,992
CATX icon
15
Perspective Therapeutics
CATX
$476M
$11M 2.63%
+2,627,107
NERV icon
16
Minerva Neurosciences
NERV
$241M
$9.97M 2.4%
1,655,500
IPSC icon
17
Century Therapeutics
IPSC
$402M
$9.17M 2.21%
4,059,054
+2,637,522
ALMS
18
Alumis Inc
ALMS
$2.79B
$8.65M 2.08%
+392,574
SABS icon
19
SAB Biotherapeutics
SABS
$290M
$8.42M 2.02%
2,198,502
ERAS icon
20
Erasca
ERAS
$3.54B
$6.84M 1.64%
422,543
-3,467,089
IKT icon
21
Inhibikase Therapeutics
IKT
$226M
$6.02M 1.45%
3,581,603
MAZE
22
Maze Therapeutics
MAZE
$1.45B
$5.97M 1.44%
+200,000
ANTX icon
23
AN2 Therapeutics
ANTX
$181M
$5.58M 1.34%
+1,661,073
LXEO icon
24
Lexeo Therapeutics
LXEO
$409M
$5.33M 1.28%
928,593
+753,593
HLXC
25
Helix Acquisition Corp III
HLXC
$225M
$5.08M 1.22%
+500,000
1
2